Week of July 13, 2026. Three things worth knowing.
1. Seven quality-system breakdowns in one small firm. It is really one breakdown.
FDA posted a warning letter to a small ophthalmic device firm on July 7 (it is in the public Warning Letters database; I am leaving the name out because the lesson matters more than the logo), following an inspection of the firm’s facility last fall. The list is long. No CAPA opened since August 2023. A backlog of more than 177 complaints, unreviewed and uninvestigated, including three reports that a handpiece charger smoked or blew up, none evaluated for MDR reportability. No device history record procedure at all. No internal audits since August 2023, and no procedure for conducting them. No design-change control on a charger substitution. No quality agreement with the contract manufacturer of the companion cleanser. A VP of Operations with zero quality-system training across a 26-month tenure. And the complaint-handling finding is a repeat from a 2019 inspection.
I have walked into rooms like this. In 25 years I have never seen a firm with a healthy CAPA program and a dead complaint file, or current training records next to a two-year audit gap. These subsystems decay together, because they are all fed by the same governance rhythm: management review, internal audit, training. When that rhythm stops, everything downstream starts rotting at roughly the same rate. So the diagnostic is one question, not seven: when was your last documented management review? If the answer requires searching, assume the rest of the stack looks like this letter. One more detail worth sitting with: FDA told the firm its remediation must meet the QMSR requirements that took effect February 2, 2026, even though the inspection ran under the old regulation.
So what: small-firm quality collapse is one disease with seven symptoms, and the letter is what it looks like when nobody takes the pulse for two years. Now what: pull four records this week: your last management review, your last internal audit, your last closed CAPA, and the training file of your newest quality-critical hire. If any of the four is more than a year old, that is where your seven-symptom risk lives.
2. The claims came down twice. Then they went back up, and FDA was still watching.
A second warning letter posted the same day, to a maker of UVC disinfection systems, is a different animal: no quality-system citations at all. The firm markets its systems for disinfecting healthcare equipment. FDA first raised the intended-use problem in a February 2022 letter. The firm removed the healthcare claims in March 2024, and again in July 2024 after FDA followed up. On May 11, 2026, FDA re-reviewed the marketing and found the claims restored. Hence the warning letter. The agency’s theory is that disease-mitigation and disinfection claims make these products devices requiring premarket review, and it rejected the firm’s reliance on the medical washer-disinfector exemption because the products lack the cleaning step that defines that category. FDA also objected to “FDA registered” language in a brochure as creating a false impression of approval or clearance under 21 CFR 807.39.
For a borderline product, your marketing copy is your intended use, and your intended use is your regulatory status. There is no separate filing cabinet where the “real” claims live. And the four-year correspondence history is the lesson inside the lesson: claims removed under FDA pressure are not forgotten. Republish them and your correspondence file becomes an escalation record.
So what: your website is labeling, and FDA reads it more than once, sometimes years apart. Now what: if you sell anything near the device boundary (disinfection, hygiene, wellness), have someone outside marketing inventory every live claim this quarter and map each one to the regulatory rationale on file. Then compare what your pages say today against what you last told FDA. Any daylight between the two is your exposure.
3. The report almost nobody files: corrections and removals under 21 CFR 806.
Buried in the same letter from item 1 is a violation worth its own item. When the firm’s chargers started smoking, it swapped the Type G chargers for USB-A versions in October 2024. A field fix for a safety problem, done quietly. The problem: 21 CFR 806.10 requires a written report to FDA within 10 working days when you initiate a correction or removal to reduce a risk to health. No report was filed, and FDA noted none existed as of the May 2026 inspection close-out, more than 18 months after the fix. That silence became its own misbranding count under 21 U.S.C. 352(t)(2).
The instinct that gets firms here is a decent one: something is wrong, fix it fast. The miss is that a quiet fix for a health risk is itself reportable, and the regulation does not care that the fix worked. Part 806 has a narrow lane for non-reportable actions, but you have to document that determination under 806.20, not just skip the paperwork.
So what: the corrections-and-removals report is the most commonly forgotten obligation in device compliance, because it triggers exactly when everyone is focused on the fix instead of the filing. Now what: audit your last five field actions. Each one should trace to either an 806 report or a documented rationale for why none was required. Then add a gate to your change-control form: does this change touch product already in the field, and why is the change being made? Those two questions catch the 806 trigger before it becomes a warning letter line item.
Facts in items 1 through 3 are from two FDA warning letters posted July 7, 2026, both available in the public FDA Warning Letters database. Firm names are omitted by editorial policy: the lessons matter more than the logos. Regulatory references are 21 CFR Part 806 (ecfr.gov) and the QMSR effective date per FDA (fda.gov).